LPMP website addresses are provided for general information, enrollment, requests for information, and data upload. Contact information is provided for the LPMP Assistant Executive Director and the Administrative Assistant. Data for 2017 cover the state population (4,682,509), DEA registered prescribers (20,129), and DEA registered dispensers (1,297). Available LPMP reports are listed. The only funding source for the LPMP reported for 2018 was controlled substance registration fees. For 2018, LPMP personnel numbers are reported for the following job categories: operational (4), technical (0.5), analytical (0.5), and "other" (0). Significant LPMP dates are enabling legislation (July 2006), becoming operational (November 2008), initial user access (January 2009), on-line access (January 2009), and electronic reporting (November 2008). Access information is provided for statutes and rules relevant to LPMP policies and procedures. Data reporting frequency is the next business day for monitored data, which cover controlled substances in schedules II, III, IV, and V. LPMP also has the authority to monitor other substances, including marijuana data, ARCOS data, and drug manufacturers or distribution data. Miscellaneous capabilities and policies are also listed. The LPMP requires that when dispensing monitored drugs, the patient must appear in person by appointment with two forms of ID, be administered required questions, and discuss results. Prescribers, but not dispensers, are required to enroll in and use the LPMP. Law enforcement agencies' access to LPMP patient data requires an active investigation of the patient, a subpoena, court order, probable cause, search warrant, or a show of proper need. No data-retention policies are noted. Training in LPMP use is available, but not required. Technological capabilities are noted, along with authorized requestor reports.
Prescription Drug Monitoring Program: Louisiana State Profile
NCJ Number
253004
Date Published
August 2018
Length
8 pages
Annotation
Information and data are presented for the Louisiana Prescription Monitoring Program (LPMP), which is administered by the Louisiana Board of Pharmacy.
Abstract